...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States.
【24h】

Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States.

机译：丙型肝炎患者的保险状况和治疗候选资格：来自美国的基于人群的数据分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Successful treatment with antiviral therapy could potentially reduce morbidity and mortality in patients with hepatitis C virus (HCV) infection. However, at the population level, these benefits may be offset by a limited number of patients who have access to antiviral treatment. Using data from the National Health and Nutrition Examination Survey conducted in 2005-2008, we analyzed the health insurance status and treatment candidacy of HCV-positive (HCV+) individuals. A total of 10,582 subjects were examined; of those, 1.16% had detectable HCV RNA and were defined as HCV+. The HCV+ patients were less likely to be insured than HCV-negative individuals (61.2% versus 81.2%; P = 0.004). Among those with health insurance, HCV+ patients were less likely to have private insurance, whereas the coverage by Medicare/Medicaid and other government-sponsored plans was similar to the rest of the population. In multivariate analysis, HCV infection was an independent predictor of being uninsured even after adjustment for demographic disparity of the HCV+ cohort (odds ratio, 0.43; 95% confidence interval, 0.24-0.78). Of all HCV+ patients, 66.7% were eligible for anti-HCV treatment. However, only 54.3% of HCV+ treatment candidates had any type of insurance coverage. Finally, only 36.3% of HCV+ patients were potentially eligible for treatment and had health insurance. CONCLUSION: A high proportion of HCV+ patients are currently uninsured, and many have publicly funded health insurance. Among those who could be candidates for treatment, the rate of insurance coverage is even lower. These findings can have important implications for health insurance coverage of these patients under the new health care reform legislation in the United States.
机译：抗病毒疗法的成功治疗可能会降低丙型肝炎病毒（HCV）感染患者的发病率和死亡率。但是，在人群水平上，有限的可获得抗病毒治疗的患者可能会抵消这些好处。我们使用2005-2008年进行的全国健康与营养检查调查的数据，分析了HCV阳性（HCV +）个人的健康保险状况和治疗候选资格。总共检查了10,582名受试者;其中1.16％的患者可检测到HCV RNA，并被定义为HCV +。与HCV阴性的个体相比，HCV +的患者被保险的可能性较小（61.2％对81.2％; P = 0.004）。在拥有健康保险的人中，HCV +患者不太可能拥有私人保险，而Medicare / Medicaid和其他政府资助的计划所覆盖的人群与其余人群相似。在多变量分析中，即使调整了HCV +队列的人口统计学差异（赔率，0.43; 95％置信区间，0.24-0.78），HCV感染仍是未保险的独立预测因素。在所有HCV +患者中，有66.7％符合抗HCV治疗的条件。但是，只有54.3％的HCV +治疗候选人拥有任何类型的保险。最后，只有36.3％的HCV +患者有资格接受治疗并拥有健康保险。结论：目前有很大比例的HCV +患者没有医疗保险，并且许多人已经获得了公共资助的健康保险。在可能成为治疗对象的那些人中，保险的覆盖率甚至更低。根据美国新的医疗保健改革立法，这些发现可能会对这些患者的医疗保险覆盖率产生重要影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号